ImmuPharma plc (AIM:IMM)

London · Delayed Price · Currency is GBP · Price in GBX

4.550

-0.200 (-4.21%)

At close: Mar 25, 2026

Revenue by Segment

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Development and Commercialisation of Pharmaceutical Products				118.35K	126.67K	77.93K	81.28K	150.46K
Development and Commercialisation of Pharmaceutical Products Growth				-6.57%	62.55%	-4.13%	-45.98%	-8.69%
Total				118.35K	126.67K	77.93K	81.28K	150.46K
Total Growth				-6.57%	62.55%	-4.13%	-45.98%	-8.69%

Revenue by Geography

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
France				68.11K	105.14K	54.75K	77.34K	150.46K
France Growth				-35.22%	92.04%	-29.21%	-48.60%	-8.69%
Switzerland				50.24K	21.53K	23.18K	3.94K	-
Switzerland Growth				133.42%	-7.12%	487.78%	-	-
Total				118.35K	126.67K	77.93K	81.28K	150.46K
Total Growth				-6.57%	62.55%	-4.13%	-45.98%	-8.69%

Source: S&P Global Market Intelligence.